Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment
Information source: Northwestern University
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Nasal Carriers of Staphylococcus Aureus
Intervention: Neosporin (polymyxin B 5,000units, Bacitracin 400 units, Neomycin 3.5mg) (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Northwestern University Official(s) and/or principal investigator(s):
Peter Lio, MD, Principal Investigator, Affiliation: Northwestern Unviersity
Overall contact:
Jennifer Hensley, MD, Phone: 312-695-0287, Email: j-hensley@northwestern.edu
Summary
Staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in
about 30% of healthcare workers. Applying mupirocin ointment, a prescription, to the
nostrils twice daily for 5 days is the current standard of care for treatment to clear this
bacteria. This research study is designed to determine the rate of clearance of this
bacteria in healthcare workers who are carriers when using triple antibiotic ointment
instead of mupirocin ointment.
Clinical Details
Official title: Clearance of Nasal Staphylococcus Aureus Colonization With Triple Antibiotic Ointment
Study design: Treatment, Open Label, Single Group Assignment
Primary outcome: The primary objective of this study is to determine the success rate of triple antibiotic ointment in eradicating S. aureus from the nares
Secondary outcome: The secondary objective of this study is to assess the success rate of triple antibiotic ointment in eradicating S. aureus compared to mupirocin ointment.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Willing and able to give informed consent
- Must have consented prior to registration for the study
Exclusion Criteria:
- active infection
- concurrent treatment with antibiotics, topical or systemic
- S. aureus decolonization attempt in prior six months
- history of HIV
- chemotherapy or systemic immunosuppressive therapy
- history of neomycin allergy or sensitivity
Locations and Contacts
Jennifer Hensley, MD, Phone: 312-695-0287, Email: j-hensley@northwestern.edu
Northwestern University, Chicago, Illinois 60611, United States; Recruiting
Peter Lio, MD, Principal Investigator
Additional Information
Starting date: September 2009
Last updated: October 16, 2009
|
